Vysis ALK Break Apart FISH Probe Kit
Abbott Molecular, Inc. · Decision date Aug 5, 2025
What did the FDA approve?
FDA records P110012/S022 as a supplement to PMA P110012, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 5, 2025.
FDA approval order statement
Approval of the expansion of the Indications for Use for the Vysis ALK Break Apart FISH Probe Kit to include an indication for ENSACOVE (ensartinib). The device, as modified, will be marketed under the trade name Vysis ALK Break Apart FISH Probe Kit and is indicated for:INTENDED USE The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) tissue specimens from non-small cell lung cancer (NSCLC) patients.INDICATION FOR USE The Vysis ALK Break Apart FISH Probe Kit is indicated as an aid in identifying patients eligible for treatment with XALKORI (crizotinib), ALUNBRIG (brigatinib), and ENSACOVE (ensartinib) in accordance with the approved therapeutic product labeling.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Aug 5, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P110012/S022
- Regulatory pathway
- PMA supplement
- Applicant
- Abbott Molecular, Inc.
- Product code
- OWE
- Decision code
- APPR
- Decision date
- Aug 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Fluorescence In Situ Hybridization, Anaplastic Lymphoma Kinase, Gene Rearrangement.
- Applicant
- Abbott Molecular, Inc.
- Product code
- OWE
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110012/S022 received
Application receipt date recorded by FDA.
P110012/S022 · FDA decision
Normal 180 Day Track
P110012/S023 · Related supplement
Vysis ALK Break Apart FISH Probe Kit
Timeline entries are records held by MedtechLedger for P110012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Vysis ALK Break Apart FISH Probe KitP110012/S023 | Abbott Molecular, Inc. | PMA supplement | Feb 18, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Molecular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1300 E Touhy Ave., Des Plaines, IL, 60018
Sources and methodology
- Original FDA record: P110012/S022
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records